- Home
- WSO vs GMAB Comparison
WSO vs GMAB Comparison
Compare WSO & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSO
- GMAB
- Stock Information
- Founded
- WSO 1945
- GMAB 1999
- Country
- WSO United States
- GMAB Denmark
- Employees
- WSO N/A
- GMAB N/A
- Industry
- WSO Industrial Machinery/Components
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- WSO Consumer Discretionary
- GMAB Health Care
- Exchange
- WSO Nasdaq
- GMAB Nasdaq
- Market Cap
- WSO 18.6B
- GMAB 17.4B
- IPO Year
- WSO N/A
- GMAB N/A
- Fundamental
- Price
- WSO $338.94
- GMAB $30.47
- Analyst Decision
- WSO Hold
- GMAB Strong Buy
- Analyst Count
- WSO 8
- GMAB 6
- Target Price
- WSO $435.00
- GMAB $40.40
- AVG Volume (30 Days)
- WSO 488.2K
- GMAB 2.2M
- Earning Date
- WSO 10-29-2025
- GMAB 11-06-2025
- Dividend Yield
- WSO 3.55%
- GMAB N/A
- EPS Growth
- WSO N/A
- GMAB 132.41
- EPS
- WSO 12.87
- GMAB 25.10
- Revenue
- WSO $7,414,495,000.00
- GMAB $3,845,670,022.00
- Revenue This Year
- WSO N/A
- GMAB $24.92
- Revenue Next Year
- WSO $5.08
- GMAB $15.97
- P/E Ratio
- WSO $26.25
- GMAB $1.21
- Revenue Growth
- WSO N/A
- GMAB 29.57
- 52 Week Low
- WSO $337.58
- GMAB $17.24
- 52 Week High
- WSO $571.42
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- WSO 33.45
- GMAB 57.23
- Support Level
- WSO $344.52
- GMAB $30.08
- Resistance Level
- WSO $355.57
- GMAB $30.78
- Average True Range (ATR)
- WSO 9.60
- GMAB 0.70
- MACD
- WSO -0.52
- GMAB 0.13
- Stochastic Oscillator
- WSO 5.48
- GMAB 84.70
About WSO Watsco Inc.
Watsco is the largest heating, ventilation, air conditioning, and refrigeration products distributor in North America. The company primarily operates in the United States (90% of revenue) with significant exposure in the Sunbelt states. Watsco also has operations in Canada (5% of sales) and Latin America (5% of sales). The company's customer base consists of more than 125,000 contractors that serve the replacement and new construction HVACR markets for residential and light commercial applications.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.